PKI-166 hydrochloride

This orally bioavailable, potent, and selective EGFR kinase inhibitor (IC50 = 0.7 nM) demonstrates significant anti-metastatic and anti-angiogenic activity in pancreatic cancer mouse models. It is a valuable research tool for studying EGFR-driven oncology, with applications in both in vitro biochemical assays and in vivo preclinical research.